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We conducted a study on molecular epidemiology and clinical implications of metallo-㌼-lactamase 
(MBL)-producing Pseudomonas aeruginosa isolated from urine.  Over a 10-year period from 2001 
through 2010,  a total of 92 MBL-producing P. aeruginosa urine isolates were collected from patients 
(one isolate per patient) who were admitted to 5 hospitals in Okayama Prefecture,  Japan.  When cross-
infection was suspected in the hospital,  pulsed-ﬁeld gel electrophoresis was performed.  In the resulting 
dendrogram of 79 MBL-producing P. aeruginosa urine isolates,  no identical isolates and 7 pairs of 
isolates with ｧ80ｵ similarity were found.  The bioﬁlm-forming capabilities of 92 MBL-producing P. 
aeruginosa urine isolates were signiﬁcantly greater than those of 92 non-MBL-producing urine isolates 
in a medium of modiﬁed artiﬁcial urine.  The imipenem resistance transferred in 16 of 18 isolates 
tested,  and these frequencies were in the range of 10－3 to 10－9.  All of 18 isolates tested belonged to 
internationally spread sequence type 235 and had 3 gene cassettes of antimicrobial resistance genes in 
the class 1 integron.  The strong bioﬁlm-forming capabilities of MBL-producing P. aeruginosa urine 
isolates could be seriously implicated in nosocomial infections.  To prevent spread of the organism and 
transferable genes,  eﬀective strategies to inhibit bioﬁlm formation in medical settings are needed.
Key words: Pseudomonas aeruginosa,  metallo-β-lactamase,  molecular epidemiology,  bioﬁlm,  urinary tract 
infection
seudomonas aeruginosa is one of the most common 
pathogens in complicated urinary tract infec-
tions (UTIs),  and is mostly responsible for nosoco-
mial or catheter-associated UTIs [1].  P. aeruginosa 
presents a serious therapeutic challenge.  The most 
problematic characteristic of the pathogen is its ability 
to rapidly develop resistance during the course of 
treating an infection [2].  Moreover,  the continuation 
of ineﬀective antimicrobial therapy promotes resis-
tance of P. aeruginosa and bioﬁlm formation.  P. aerugi-
nosa has a tendency to form bioﬁlms on the surface of 
urinary catheters in particular [3].  Antimicrobial 
therapy for P. aeruginosa-bioﬁlm infections in the uri-
nary tract is limited [4].
　 Acquisition of a metallo-β-lactamase (MBL) gene 
will invariably mediate broad-spectrum β-lactam resis-
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tance in P. aeruginosa [5,  6].  The genes encoding 
MBLs are often procured by class 1 integrons,  which 
are found in transposons,  resulting in highly transmis-
sible genetic elements [7].  Moreover,  other gene 
cassettes within the integrons often confer resistance 
to aminoglycosides,  precluding their use as an alter-
native treatment.  In 1991,  the ﬁrst mobile MBL in a 
P. aeruginosa strain was reported in Japan [8].  The 
imipenem-resistance allele was found on a transferable 
conjugative plasmid that could be readily mobilized to 
other P. aeruginosa strains.  The identical gene was 
reported in Serratia marcescens isolated from a hospital 
in Japan in 1991 and later designated blaIMP-1 [9].  
Since then,  a large variety of MBLs have been 
described in bacteria of many genera and species 
worldwide [5,  6,  10].  MBL-producing P. aeruginosa 
is one of the most recalcitrant hospital-associated 
pathogens and some outbreaks of infections with mul-
tidrug-resistant P. aeruginosa or MBL-producing P. 
aeruginosa in Japanese hospitals have been reported 
[11-13].  There is thus an urgent need for strategies 
to prevent the spread of this organism in a medical 
setting.
　 MBL-producing P. aeruginosa was isolated ﬁrst at 
Okayama University Hospital in 2001.  Since then,  we 
have investigated cross-infections in 5 hospitals in 
Okayama prefecture,  Japan by using pulsed-ﬁeld gel 
electrophoresis (PFGE).  In this study,  we speciﬁ-
cally focused on MBL-producing P. aeruginosa isolated 
from urine in order to develop more eﬀective strate-
gies for infection control in hospitals.  We examined 
MBL-producing P. aeruginosa isolated from urine to 
determine its bioﬁlm-forming capabilities and its anti-
microbial resistance transfer,  and performed addi-
tional studies on the molecular epidemiology of these 
isolates by using multilocus sequence typing (MLST) 
and analysis of integron cassettes.
Materials and Methods
　 Clinical isolates. Over a 10-year period from 
2001 to 2010,  a total of 92 MBL-producing P. aerugi-
nosa urine isolates were collected from patients (one 
isolate per patient) who were admitted to 5 hospitals 
in Okayama Prefecture,  Japan.  For purpose of com-
parison,  92 non-MBL-producing P. aeruginosa urine 
isolates,  which were collected from patients (one iso-
late per patient) attending the urology clinic of 
Okayama University Hospital over a 10-year period 
from 2001 to 2010,  were used.
　 Polymerase chain reaction (PCR) analysis.
The presumed MBL-producing P. aeruginosa urine 
isolates were tested by PCR analysis to conﬁrm the 
presence of the blaIMP-1 gene by using the primers 
(IMP1-f and IMP1-r) described by Arakawa et al.  
[14] (Table 1).  All isolates were cultured on 
Mueller-Hinton agar plates overnight.  The resulting 
P. aeruginosa colonies were picked with sterilized 
toothpicks.  They were shaken in microtubes (volume,  
1.5ml) with 50µl of 7.5ｵ Chelex-100 solution (Bio-
Rad Laboratories K. K.,  Tokyo,  Japan) in distilled 
water,  and were heated at 100℃ for 10min to pre-
pare crude genomic DNA lysates.  The mixture was 
vortexed for approximately 30 sec at room tempera-
ture and then centrifuged at 10,000×g for 1min.  The 
supernatant (2.5µl) was mixed with 22.5µl of prepared 
reaction mixture to start the reaction.  The 25-µl 
reaction volume contained 0.1µM of each primer,  
10mM Tris-HCl (pH8.3),  50mM KCl,  1.5mM MgCl2,  
0.2mM of each deoxynucleotide triphosphate (dATP,  
dCTP,  dGTP,  and dTTP),  and 0.625 U of Taq DNA 
polymerase (TaKaRa Bio Inc.,  Otsu,  Japan).  PCR 
ampliﬁcation was carried out with the following ther-
mal cycling proﬁle: initial denaturation at 94℃ for 
2min,  30 cycles of ampliﬁcation (denaturation at 
94℃ for 1min,  annealing at 55℃ for 1min,  and 
extension at 72℃ for 1.5min),  and a ﬁnal extension at 
72℃ for 5min in a GeneAmp 9700 PCR system (Life 
Technology Corp.  (formerly Applied Biosystems Inc.),  
Carlsbad,  CA,  USA).  PCR products were analyzed 
on a 1.2ｵ SeaKem ME agarose gel (Lonza Walkersville 
Inc.  (formerly FMC BioProducts Inc.),  Walkersville,  
MD,  USA) with 1×Tris-borate-EDTA buﬀer.  After 
electrophoresis,  the gels were stained with ethidium 
bromide (1mg/l) and photographed under a UV trans-
illuminator.  A 100-bp DNA ladder (New England 
Biolabs Japan Inc.,  Tokyo,  Japan) was used as the 
molecular size marker and the fragment size of the 
PCR product was 587bp.  In this study,  blaIMP-1-posi-
tive isolates of P. aeruginosa were used as MBL-
producing isolates.
　 Pulsed-ﬁ eld gel electrophoresis (PFGE).
PFGE of MBL-producing P. aeruginosa urine isolates 
was performed by using the standard procedures 
according to the manufacturerʼs protocol (Bio-Rad 
Laboratories).  Brieﬂy,  isolates were grown in tryptic 
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soy broth at 37℃ overnight.  Bacterial cultures were 
embedded in 0.7ｵ agarose plugs,  lysed,  washed,  and 
digested separately with SpeI restriction enzyme.  
Size separation of the resulting DNA fragments was 
performed for 18.5h in 0.8ｵ agarose gels by using a 
CHEF DR-III apparatus (Bio-Rad Laboratories);  
voltage was set at 6V/cm with switch times of 1 sec to 
23 sec at 14℃.  A lambda ladder was used as a refer-
ence size standard.  Pattern images were captured 
with a GelDoc XR (Bio-Rad Laboratories).  The relat-
edness of each PFGE ﬁngerprint was determined 
using Fingerprinting II (Bio-Rad Laboratories) and 
interpreted by the criteria proposed by Tenover et al.  
[15].  In the dendrogram analysis,  isolates with band 
patterns that were 100ｵ similar were considered to 
be of identical type,  and those with ｧ80ｵ similarity 
were considered to have clonal relationships.
　 Susceptibility testing. Antimicrobial suscepti-
bilities of MBL-producing P. aeruginosa urine isolates 
were determined by the standard broth microdilution 
method using a dry plate DP-25 (Eiken Chemical Co.,  
Ltd.,  Tokyo,  Japan) in accordance with Clinical and 
Laboratory Standards Institute guidelines [16].  
According to the Law Concerning the Prevention of 
Infections and Medical Care for Patients with 
Infections of the Japanese Ministry of Health,  Labour 
and Welfare,  multidrug-resistant P. aeruginosa (MDRP) 
was deﬁned as an isolate for which the minimum 
inhibitory concentrations (MICs) of imipenem,  cipro-
ﬂoxacin and amikacin were ｧ16,  ｧ4 and ｧ32µg/ml,  
respectively [17].
　 Bioﬁ lm formation assay. We used an in vitro 
microtiter plate assay to quantify bioﬁlm formation 
[18].  The MBL-producing and non-MBL-producing P. 
aeruginosa urine isolates were grown overnight at 37℃ 
in medium of artiﬁcial urine supplemented with 0.4ｵ 
nutrient broth (Nissui Pharmaceutical Co.,  Ltd.,  
Tokyo,  Japan) [19].  The culture was diluted 1 : 100 
in medium,  and 200µl of this cell suspension was used 
to inoculate sterile ﬂat-bottomed 96-well polystyrene 
microtiter plates (Nunc 167008; Thermo Fisher 
Scientiﬁc K. K.,  Yokohama,  Japan).  After 24h at 
37℃ without shaking,  the wells were gently washed 3 
times with 300µl of distilled water,  dried in an 
inverted position for 10min,  and stained with 200µl 
of 0.3ｵ crystal violet solution in water for 45min.  
After staining,  the plates were washed 3 times with 
distilled water.  Quantitative analysis of bioﬁlm pro-
duction was performed by adding 300µl of ethanol-
acetic acid (95 : 5,  vol/vol) to destain the wells.  One 
hundred microliters from each well was transferred to 
a new microtiter plate,  and the level (optical density;  
OD) of crystal violet present in the destaining solution 
was measured at 570nm using a model 680 microplate 
reader (Bio-Rad Laboratories).  Each assay was per-
formed in triplicate.  As a control,  uninoculated medium 
was used to determine the background OD.  The mean 
OD570 value from the control wells was subtracted 
from the mean OD570 value of tested wells.  The bio-
ﬁlm-forming capabilities were arbitrarily classiﬁed 
into 3 groups: strong (OD570ｧ1),  medium (OD570ｧ
0.5 to＜1) and weak (OD570ｧ0 to＜0.5) bioﬁlm form-
ers [20].  Data are expressed as the mean values ± 
standard error (SE).  The Mann-Whitney U test was 
used to compare the bioﬁlm-forming capabilities 
between the 2 groups of MBL-producing and non-
MBL-producing isolates.  All results were considered 
statistically signiﬁcant at the p＜0.05 level.
　 Conjugative transfer experiments. Filter 
mating was performed using each of the MBL-
producing P. aeruginosa isolates as a donor and P. 
aeruginosa ML5017 as a recipient to determine the 
transferability of the carbapenem-resistance determi-
nant.  The P. aeruginosa ML5017 recipient strain was 
kindly provided by Shizuko Iyobe [21].  Overnight 
cultures of 50µl of donor and 0.5ml of recipient were 
added to 4.5ml of fresh Mueller-Hinton broth,  and the 
mixtures were immediately collected on a membrane 
(25mm width 0.45µm pore size ﬁlter,  type HA; EMD 
Millipore Corp.,  Billerica,  MA,  USA),  which was 
inverted onto the surface of a Mueller-Hinton agar 
plate.  After incubation at 37℃ for 20h,  the cells 
were suspended in 1ml of Mueller-Hinton broth and 
the portions (0.1ml) of the mixed and diluted culture 
were then plated on Mueller-Hinton agar plates with 
appropriate selective antimicrobial agents.  Trans-
conjugants were selected on Mueller-Hinton agar plates 
supplemented with 8µg/ml of imipenem and 100µg/ml 
of rifampicin.  Colonies were counted after 20h of 
incubation at 37℃.  Separate platings where donors 
alone were selected provided a basis for estimating the 
transfer frequency (per donor).  Transfer frequencies 
were calculated as the number of transconjugants per 
donor cell.
　 Multilocus sequence typing (MLST). MLST 
was performed according to the protocols described on 
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the P. aeruginosa MLST Database website (http://
pubmlst.org/paeruginosa/) (accessed August,  2013).  
PCR and sequencing were performed for 7 house-
keeping genes (acsA,  aroE,  guaA,  mutL,  nuoD,  ppsA 
and trpE) [22].  Brieﬂy,  the ampliﬁcation product was 
puriﬁed using a QIAquick PCR Puriﬁcation Kit 
(QIAGEN K. K.,  Tokyo,  Japan).  The DNA concen-
tration of the puriﬁed product was measured with a 
NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies Inc.,  Wilmington,  DE,  USA).  The 
puriﬁed product with 8ng of DNA was used for direct 
sequencing on each DNA strand,  and a BigDye 
Terminator version 1.1 Cycle Sequencing Kit (Life 
Technology) was used to perform ﬂuorescent labeling.  
Unincorporated dye terminators were removed by 
precipitation with 70ｵ ethanol.  The resulting product 
was dehydrated and stored at 4℃.  The dried PCR 
product was dissolved in 15µl of Hi-DiTM formamide,  
and then sequencing was performed.  An ABI 3130xl 
Genetic Analyzer (Life Technology) at the Central 
Research Laboratory,  Okayama University Medical 
School was used to decode the base sequences.  The 
nucleotide sequences of these genes were compared 
with the sequences submitted to the MLST database 
to determine the allelic numbers and sequence types 
(STs).
　 PCR ampliﬁ cation of variable regions of the 
blaIMP-1-containing integrons. To determine the 
content and order of genes in the variable regions of 
the blaIMP-1-containing integrons,  PCR ampliﬁcations 
were carried out with the primers listed in Table 1.  
The presence of the genes (intl1,  blaIMP-1,  aac6ʼ-Iae,  
aadA1,  qacEΔ1,  sul1,  orf5,  IS1326,  IS1353,  tniBΔ1,  
tniAΔ,  IS26) and the position of integration of these 
genes were veriﬁed.  The gene cassette array (Fig.  1) 
was composed as reported previously according to the 
sequence of entire variable regions encoding integrase 
(intl1),  metallo-β-lactamase (blaIMP-1),  aminoglycoside 
acetyltransferase (aac6ʼ-Iae); aminoglycoside adenyl-
transferase (aadA1); resistance to quaternary ammo-
nium compound disinfectants (qacEΔ1),  sulfonamide 
resistance (sul1); an open reading frame (orf5) of 
unknown function; IS,  insertion sequence (IS1326,  
IS1353,  IS26) and a partial integron transposition 
module (tniBΔ1,  tniAΔ) [11,  23].  PCR procedures 
were performed as described above,  and PCRs were 
ampliﬁed with TaKaRa Taq,  Hot Start Version 
according to the manufacturerʼs protocol (TaKaRa 
Bio).  The ampliﬁcation conditions of the primer pairs 
shown in Table 1 (amplicon number: 1,  2,  4 to 11 
and 16 in Fig.  1) were 95℃ for 2min,  followed by 30 
cycles of 94℃ for 1min,  50℃ for 1min,  and 72℃ 
for 3min,  and those of the primer pairs in Table 1 
(amplicon number: 12 to 15,  17 and 18 in Fig.  1) 
were 95℃ for 2min,  followed by 25 cycles of 98℃ 
for 10sec,  50℃ for 30sec,  and 72℃ for 1min.  
PCR ampliﬁcation using the primer pair shown in 
Table 1 (amplicon number 3 in Fig.  1) and the condi-
tions described above was used to conﬁrm the pres-
ence of the blaIMP-1 gene.
Results
　 PFGE analysis. PFGE analysis was per-
formed when cross-infection was suspected in the 
hospital.  In the resulting PFGE dendrogram of 79 
MBL-producing P. aeruginosa urine isolates,  no identi-
cal isolates and 7 pairs of isolates with ｧ80ｵ simi-
larity were found (Fig.  2).  The 7 pairs of isolates 
having a clonal relationship were identiﬁed in 3 diﬀer-
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Fig. 1　 PCR ampliﬁcation of variable regions of the blaIMP-1-containing integrons.  The genes (A: intl1 ; B: blaIMP-1; C: aac6 ʼ
-Iae; D: aadA1 ; E: qacEΔ1 ; F: sul1 ; G: orf5 ; H: IS26 ; a: IS1326 ; b: IS1353 ; c: tniBΔ1 ; d: tniAΔ) in blaIMP-1-containing integrons 
were ampliﬁed by PCR with primers as previously reported (Table 1).  Open reading frames are shown as arrows indicating the orientation 
of the coding sequence.  The rectangles (amplicon number: 1 to 18) indicate the position and size of PCR products.
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Table 1　 PCR primers used in this study
Name of
primer Sequence (5ʼ→3ʼ)
Expected size of
amplicon (bp)
Amplicon
number in
Fig. 1
Reference
number
int1-F TGCGTGTAAATCATCGTCGT
766  1 11int1-R CGAAGTCGAGGCATTTCTGT
int1imp1-F AGCACCTTGCCGTAGAAGAA
695  2 11int1imp1-R TTTTATAGCCACGCTCCACA
IMP1-f ACCGCAGCAGAGTCTTTGCC
587  3 14IMP1-r ACAACCAGTTTTGCCTTACC
imp1aacS1-F AAAGGCAGCATTTCCTCTCA
737  4 11imp1aacS1-R GACGGCCAAGAATCGAAAT
aacS1-FC ATGAAATACAACATTGTTAATATTA
552  5 11aacS1-RC TTACATTATATTTTTCCACATTAAT
aacS1aadA1-F ATTGTGTGGTTGGGTTGGAT
691  6 11aacS1aadA1-R GGAGAATCTCGCTCTCTCCA
aadA1-F TGATTTGCTGGTTACGGTGA
451  7 11aadA1-R TACTGCGCTGTACCAAATGC
aadA1qacEd-F TGATTTGCTGGTTACGGTGA
873  8 11aadA1qacEd-R ATGCGGATGTTGCGATTACT
qacEdelta-F TGAAAGGCTGGCTTTTTCTT
286  9 11qacEdelta-R GCAATTATGAGCCCCATACC
qacEdsul-F TCGGTGTTGCTTATGCAGTC
306 10 11qacEdsul-R ACATCCACGACGTCTGATCC
sul-F TCACCGAGGACTCCTTCTTC
759 11 11sul-R GGGTTTCCGAGAAGGTGATT
istA-955f CGAGTCACTTCAACCTGCCT
530 12 23istA-r TAGCGGTTCACGTTGGCCTG
istA-105f GTATTTGCAAAGCAAGGTGG
190 13 23istA-294r TCGGTCATAAGACCCGGTAA
AB104852-8121f AGTAGATCACTATATCGAAC
260 14 23AB104852-8380r AGTTATACAACGTTGGTCGC
AB104852-9211f GAAAATGCCCAATTAACGCG
140 15 23AB104852-9350r ATGAGGTCTTTCAGCGTCAC
tniB-F CAGAGCCAGTTGCTCCATTT
399 16 11tniB-R ATCATCGACCTGTCCCACCT
IS26R-414f TAAAGCGCCCGCCTATGGTC
595 17 23tniA-1622r TCGGCAATATCCGTATCCGG
IS26R-f ATGAACCCATTCAAAGGCCG
558 18 23IS26R-558r CGTGGCGCCGATTATCCGTT
ent hospitals,  and each of 2 pairs of isolates from 2 
diﬀerent hospitals was detected over a 4-day or 5-day 
interval.  According to our records,  the results con-
ﬁrmed that no spread occurred between 5 diﬀerent 
hospitals and suggested that a cross-infection occurred 
within each of 2 hospitals.  The other 5 pairs of iso-
lates from 3 diﬀerent hospitals were detected over 
approximately 1-month to 3-month intervals.
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Fig. 2　 PFGE dendrogram of 79 MBL-producing P. aeruginosa urine isolates.  The corresponding banding pattern after SpeI digestion and 
subsequent PFGE is shown for each isolate.  The scale bar at the top of the dendrogram indicates the similarity.  The dotted line indicates 
the cutoﬀ value of 80ｵ similarity.  This cutoﬀ for clonal relationship was chosen if the PFGE patterns diﬀered by changes consistent with 
a single genetic event,  i.e.,  a point mutation or an insertion or deletion of DNA [15],  which in this PFGE setup corresponded to approxi-
mately 80ｵ similarity.
　 Antimicrobial susceptibility and bioﬁ lm-
forming capabilities. Of the 92 MBL-producing 
isolates,  83 (90.2ｵ) were resistant to imipenem,  
ciproﬂoxacin and amikacin (MDRP),  and 9 (9.8ｵ) 
were resistant to imipenem and ciproﬂoxacin.  Of the 
92 isolates,  41 (44.6ｵ),  37 (40.2ｵ) and 14 (15.2ｵ) 
isolates exhibited strong,  medium and weak bioﬁlm 
formation,  respectively.  In these 3 groups,  37 of 41 
(90.2ｵ),  35 of 37 (94.6ｵ) and 11 of 14 (78.6ｵ) iso-
lates were MDRP,  that is,  more than 90ｵ of MDRP 
exhibited strong or medium bioﬁlm formation.  As 
shown in Fig.  3,  box-and-whisker plots were used to 
compare the bioﬁlm-forming capabilities of MBL-
producing and non-MBL-producing P. aeruginosa iso-
lates in a medium of modiﬁed artiﬁcial urine.  The 
average values of OD570 (mean ± SE) for each group 
(n＝92) were 1.17±0.08 and 0.34±0.05,  respec-
tively.  The bioﬁlm-forming capabilities of MBL-
producing isolates were signiﬁcantly greater than 
those of non-MBL-producing isolates (p＜0.001).
　 Carbapenem-resistance transfer. A total of 
18 MBL-producing isolates (MDRP) classiﬁed into 3 
groups according to their bioﬁlm-forming capabilities 
(8,  6 and 4 isolates in the strong,  medium and weak 
bioﬁlm formation groups,  respectively) were selected 
on the basis of their distinct PFGE patterns with less 
than 55ｵ similarity.  The imipenem resistance was 
transferred in 16 of 18 isolates tested,  and these 
frequencies were in the range of 10－3 to 10－9 (Table 
2).  In the 3 groups according to bioﬁlm-forming capa-
bility,  2 of 8,  1 of 6 and 1 of 4 isolates which exhib-
ited strong,  medium and weak bioﬁlm formation,  
respectively,  had relatively higher frequencies in the 
range of 10－3 to 10－5.  There was no relationship 
between the bioﬁlm-forming capabilities and frequen-
cies of carbapenem-resistance transfer.
　 Multilocus sequence typing (MLST). All of 
the 18 MBL-producing isolates (MDRP) tested above 
(Table 2) were genotyped as ST235 based on the 
presence of all 7 MLST alleles (acsA 38,  aroE 11,  
guaA 3,  mutL 13,  nuoD 1,  ppsA 2 and trpE 4).
　 Structure of the blaIMP-1-containing integrons.
As shown in Fig.  1,  PCR ampliﬁcation of variable 
regions of the blaIMP-1-containing integron was per-
formed in the 18 MBL-producing isolates (MDRP).  
All of the 18 amplicons were detected in 16 of 18 
isolates tested.  In the remaining 2 isolates,  no ampli-
ﬁcation of the amplicon number 17 was detected.  As 
summarized in Table 2,  the blaIMP-1 gene was present 
in the class 1 integron (intl1-qacEΔ1-sul1-orf5) in agree-
ment with the previous studies [7,  11,  23].  In the 
integrons,  3 gene cassettes (blaIMP-1,  aac6ʼ-Iae and 
aadA1) encoding antimicrobial-resistance determinants 
and 3 insertion sequences (IS1326,  IS1353 and IS26) 
were detected in all of the 18 MBL-producing isolates 
tested.  The insertion of IS26 into the tniA-coding 
region was detected in 16 of 18 isolates.
Discussion
　 Over a 10-year period from 2001 to 2010,  we have 
performed PFGE analysis on the MBL-producing P. 
aeruginosa isolates when cross-infection was suspected 
in the hospital.  The resulting PFGE dendrogram 
suggested that the cross-infection occurred directly or 
indirectly on 7 pairs of isolates having a clonal rela-
tionship.  These pairs of isolates were detected over a 
4-day or 5-day interval or over approximately 1-month 
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Fig. 3　 Box-and-whisker plots of the bioﬁlm-forming capabilities 
(OD570 values) of P. aeruginosa urine isolates in 2 groups (n＝92).  
A bioﬁlm formation assay was performed in medium of artiﬁcial urine 
supplemented with 0.4ｵ nutrient broth [19].  The heights of the 
boxes indicate the interquartile lengths.  The central bar in each box 
is the median.  Whiskers extend to the most extreme values at 1.5 
box lengths from the edge of the box.  Black dots and asterisks 
indicate outliers beyond 1.5 and 3.0 box lengths from the edge of 
the box,  respectively.  Group I is MBL-producing P. aeruginosa 
(mean ± SE: 1.17±0.08).  Group II consists of non-MBL-produc-
ing P. aeruginosa (mean ± SE: 0.34±0.05).  The p-value was 
＜0.001.
to 3-month intervals.  Such cross-infection can occur 
when an individual is in direct contact with a contami-
nated individual or through contaminated instruments 
or environments (equipment,  work surface,  clothes,  
etc.).  PFGE is considered as the gold standard method 
for outbreak analysis [15].  However,  MBL-
producing P. aeruginosa isolates likely possess highly 
transmissible genetic elements [7].  The interpreta-
tion of PFGE patterns potentially related to cross-
infection should be made with caution.
　 P. aeruginosa is a problematic organism in acute and 
chronic human infections,  including UTIs.  P. aerugi-
nosa may produce bioﬁlm,  particularly in cases of 
chronic infection and device-related infection [3,  4,  
24,  25].  Bacterial bioﬁlms,  which are microcolonies 
encased in extracellular polysaccharide material,  
result from the adherence of bacteria to all types of 
surfaces.  The innate tolerance of bioﬁlms to antimi-
crobial therapy has led to problems in their eradica-
tion and in the management of patients with device-
related infections.  Bioﬁlms may also interfere with the 
immune clearance of infection.  In addition,  tradition-
ally described resistance mechanisms in P. aeruginosa,  
such as loss of porins,  eﬄux pumps,  and enzymatic 
production,  are responsible for the antimicrobial 
resistance [26].  The dissemination of distinct types 
of β-lactamase with hydrolytic activity against carba-
penems has been increasing worldwide [5,  6].  The 
main carbapenemases produced by P. aeruginosa include 
the MBLs,  which severely limit the treatment options 
for patients.
　 In this study,  we used a microtiter plate assay to 
quantify bioﬁlm formation in a medium of modiﬁed 
artiﬁcial urine.  The bioﬁlm-forming capabilities of 
MBL-producing P. aeruginosa urine isolates were sig-
niﬁcantly greater than those of non-MBL-producing 
urine isolates (Fig.  3).  Perez et al.  reported that P. 
aeruginosa harboring an MBL gene isolated from the 
sputa of patients with and without cystic ﬁbrosis 
showed a high-level ability to produce bioﬁlm [27].  
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Table 2　 Summary of 18 MBL-producing isolates (MDRP) tested
Isolate
number
Bioﬁlm
assay
(OD570)
Conjugation
frequencies MLST
blaIMP-1-containing integron
Class 1
integrona
Antimicrobial
resistance
genesb
Insertion
sequencesc
Truncated
tni
moduled
13 2.070 7.0×10－5 ST235 ＋ ＋ ＋ ＋
9 2.060 1.6×10－5 ST235 ＋ ＋ ＋ ＋
14 2.005 1.1×10－7 ST235 ＋ ＋ ＋ ＋
11 1.870 7.9×10－6 ST235 ＋ ＋ ＋ ＋
26 1.849 1.0×10－7 ST235 ＋ ＋ ＋ ＋
144 1.816 1.3×10－7 ST235 ＋ ＋ ＋ ＋
5 1.226 1.5×10－6 ST235 ＋ ＋ ＋ ＋
112 1.113 2.5×10－8 ST235 ＋ ＋ ＋ ＋
2 0.828 7.1×10－7 ST235 ＋ ＋ ＋ ＋
121 0.790 7.2×10－5 ST235 ＋ ＋ ＋ －
105 0.789 Not detected ST235 ＋ ＋ ＋ ＋
30 0.685 Not detected ST235 ＋ ＋ ＋ ＋
118 0.650 2.5×10－7 ST235 ＋ ＋ ＋ －
65 0.616 5.0×10－8 ST235 ＋ ＋ ＋ ＋
21 0.486 1.7×10－3 ST235 ＋ ＋ ＋ ＋
24 0.426 1.1×10－8 ST235 ＋ ＋ ＋ ＋
32 0.425 4.5×10－8 ST235 ＋ ＋ ＋ ＋
100 0.379 7.1×10－9 ST235 ＋ ＋ ＋ ＋
aClass 1 integron (intl1 -qacEΔ1 -sul1 -orf5 ) [7].
bAntimicrobial resistance genes (blaIMP-1,  aac6 ʼ-Iae,  aadA1 ) [11,  23].
cInsertion sequences (IS1326 ,  IS1353 ,  IS26 ) [11,  23].
dTruncated tni module (tniBΔ1 ,  tniAΔ) with insertion of IS26  into the tniA-coding region [11, 23].
They warned of an “overlapping of mechanisms” that 
can collectively heighten the challenge of treating 
pulmonary infections caused by P. aeruginosa.  Bioﬁlm 
formation by bacteria occurs not only with indwelling 
devices but also in response to any bacterial factor 
that mediates adherence to components of the extra-
cellular matrix of the host [3,  4,  24,  25].  On the 
other hand,  the ability of bacteria to survive in the 
hospital environment for long periods is linked to their 
antimicrobial resistance and their ability to form bio-
ﬁlms.  The strong bioﬁlm-forming capabilities of MBL-
producing P. aeruginosa can cause serious problems 
both in patients with nosocomial infections,  including 
UTIs,  and in the hospital environment.
　 Zilberberg et al.  reported on the secular trends in 
Gram-negative resistance among UTI hospitalizations 
in the United States,  from 2000 to 2009 [28].  In 
this 10-year period,  the frequency of UTI hospital-
izations increased by approximately 50ｵ and infec-
tions caused by multidrug-resistant P. aeruginosa 
increased by approximately 50ｵ,  whereas infections 
due to all Gram-negative bacteria followed a similar 
trajectory.  Catheter-associated UTI (CAUTI) is 
responsible for 40ｵ of nosocomial infections,  making 
it the most common cause of nosocomial infection [1].  
Catheterization of the urinary tract is one of the most 
common factors predisposing the host to complica-
tions [29].  Colli et al.  reported on the national 
trends in hospitalization due to indwelling urinary 
catheter complications in the United States,  from 
2001 to 2010 [30].  In this 10-year period,  the com-
plications increased almost 4-fold and the majority of 
these patients had UTIs.
　 Bioﬁlm formation is one of the prominent factors in 
bacterial diversiﬁcation and is responsible for the 
horizontal spread of antimicrobial resistance and viru-
lence genes [31,  32].  Our data showed that there was 
no relationship between the bioﬁlm-forming capabili-
ties and frequencies of carbapenem-resistance transfer 
of MBL-producing P. aeruginosa isolates (Table 2).  
Since some of the isolates at each level (strong,  
medium or weak) of bioﬁlm-formation strength had high 
frequencies of gene transfer (10－3 to 10－5),  it was 
likely that the carbapenem-resistance determinant of 
these isolates was located on a plasmid.  Antimicrobial-
resistance genes on transferable conjugative plasmids 
are more problematic than those on chromosomes in 
medical settings,  because the transmission and dis-
semination of antimicrobial-resistance determinants 
occurs more frequently among clinically relevant 
pathogenic bacteria [33].  The MBL-producing P. 
aeruginosa urine isolates must be taken into consider-
ation in regard to the dissemination of antimicrobial 
resistance and virulence genes.
　 PFGE is still the gold standard method for inves-
tigating outbreaks and local epidemiology,  and MLST 
may be more relevant to investigations exploring evo-
lutionary and population biology relationships [34,  
35].  Clinical isolates of P. aeruginosa ST235 have 
been reported worldwide and have often been shown to 
harbor clinically important acquired β-lactamases 
[36,  37].  In Japan,  MBL-producing P. aeruginosa 
ST235 have undergone clonal expansion in medical 
settings [38].  In this study,  all 18 of the MBL-
producing P. aeruginosa urine isolates (MDRP) tested 
belonged to the internationally spread strain ST235.  
A limited number of P. aeruginosa genotypes,  including 
ST235,  that are known to be high-risk clones are 
responsible for epidemics of nosocomial infections by 
multidrug-resistant P. aeruginosa worldwide [39].
　 A large variety of MBLs have been described in 
bacteria of many genera and species worldwide [5,  6,  
10].  MBLs belonging to the IMP,  VIM,  GIM,  and 
SIM types have been detected primarily in P. aerugi-
nosa.  Among them,  IMP and VIM are the most com-
mon types of MBL worldwide and the IMP type har-
boring blaIMP-1 is predominant in Japan [11,  23].  
Integrons are often found on the plasmid or as a part 
of the transposons or transmissible genetic elements 
(ISCR family) that are able to mobilize chromosomal 
elements,  resulting in an increase in the number of 
antimicrobial-resistant Gram-negative bacteria [33,  
40].  Kouda et al.  reported 6 variants in the blaIMP-1-
containing integron (polymorphs A to F).  Polymorph 
F,  which was formed by insertion of IS26 into the 
intl1 gene of polymorph E,  was ﬁrst disseminated in 
2005 in Hiroshima prefecture [23].  Our data con-
ﬁrmed that all 18 of the MBL-producing P. aeruginosa 
urine isolates (MDRP) tested belonged to polymorph 
E (Fig. 1),  and no members of polymorph F were 
found.  Kitao et al.  reported the emergence of multi-
drug-resistant P. aeruginosa isolates that produce both 
IMP-type MBLs and an aminoglycoside-modifying 
enzyme [AAC(6ʼ)-Iae]; these isolates belong to poly-
morph E and have become a serious problem in medi-
cal settings in Japan [38].
97Metallo-β-Lactamase-Producing P. aeruginosaApril 2014
　 In recent years,  clones that are resistant to many 
antimicrobial agents and carry virulence factors have 
spread globally,  and are considered highly successful 
or high-risk clones [33].  In P. aeruginosa,  AmpR,  
which regulates the expression of the chromosomal β
-lactamase AmpC,  is a global transcriptional regulator 
involved in quorum sensing,  alginate production,  bio-
ﬁlm formation,  and the expression of several other 
virulence factors [41].  Mulet et al.  explored the 
potential biological parameters that may explain the 
success of widespread P. aeruginosa high-risk clones 
producing invasive infections.  The bloodstream iso-
lates belonged to high-risk clones showed signiﬁcantly 
increased bioﬁlm formation and mutant frequencies,  
but signiﬁcantly reduced motility (twitching,  swim-
ming,  and swarming),  production of pyoverdine and 
pyocyanin,  and ﬁtness [42].  They suggested that the 
deﬁned biological markers of high-risk clones,  resem-
bling those resulting from adaptation to chronic infec-
tions,  could be useful for the design of speciﬁc treat-
ment and infection control strategies.  Although we 
have not yet studied virulence factors other than bio-
ﬁlm formation on MBL-producing P. aeruginosa urine 
isolates,  such factors will be an important research 
subject for the development of eﬀective strategies to 
inhibit bioﬁlm formation [43].
　 In conclusion,  the strong bioﬁlm-forming capabili-
ties of MBL-producing P. aeruginosa urine isolates 
could be seriously implicated in nosocomial infections.  
To prevent spread of the organism and transferable 
genes,  eﬀective strategies to inhibit bioﬁlm formation 
in medical settings are needed.
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